Literature DB >> 24851827

Statin therapy improves long-term survival in non-ischaemic cardiomyopathy: a pooled analysis of 4500 patients.

Salil V Deo1, Abeer Rababa'h2, Salah E Altarabsheh3, Ju Yong Lim4, Yang Hyun Cho5, Soon J Park6.   

Abstract

Statin therapy has demonstrated a beneficial effect in patients with chronic heart failure. While the majority of patients with ischaemic cardiomyopathy are prescribed these drugs, studies have demonstrated that less than one fifth of patients with dilated cardiomyopathy are on regular statin therapy. We have performed a meta-analysis of 4500 patients from six studies (four randomised controlled trials). Our results demonstrate that statin therapy significantly improves long-term survival in patients with non-ischaemic heart failure {Hazard ratio for mortality 0.45 (0.33-0.62); p<0.0001; I(2)=41%; p-value for heterogeneity=0.13}.
Copyright © 2014 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Dilated cardiomyopathy; Heart failure; HydroxylglutarylCoA reductase inhibitiors; Non-ischemic cardiomyopathy; Statin

Mesh:

Substances:

Year:  2014        PMID: 24851827     DOI: 10.1016/j.hlc.2014.04.007

Source DB:  PubMed          Journal:  Heart Lung Circ        ISSN: 1443-9506            Impact factor:   2.975


  7 in total

1.  PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016.

Authors:  Maciej Banach; Piotr Jankowski; Jacek Jóźwiak; Barbara Cybulska; Adam Windak; Tomasz Guzik; Artur Mamcarz; Marlena Broncel; Tomasz Tomasik; Jacek Rysz; Agnieszka Jankowska-Zduńczyk; Piotr Hoffman; Agnieszka Mastalerz-Migas
Journal:  Arch Med Sci       Date:  2016-12-19       Impact factor: 3.318

2.  Targeting Cholesterol in Non-ischemic Heart Failure: A Role for LDLR Gene Therapy?

Authors:  Alberico Luigi Catapano; Angela Pirillo; Giuseppe Danilo Norata
Journal:  Mol Ther       Date:  2017-10-19       Impact factor: 11.454

3.  PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021.

Authors:  Maciej Banach; Paweł Burchardt; Krzysztof Chlebus; Piotr Dobrowolski; Dariusz Dudek; Krzysztof Dyrbuś; Mariusz Gąsior; Piotr Jankowski; Jacek Jóźwiak; Longina Kłosiewicz-Latoszek; Irina Kowalska; Maciej Małecki; Aleksander Prejbisz; Michał Rakowski; Jacek Rysz; Bogdan Solnica; Dariusz Sitkiewicz; Grażyna Sygitowicz; Grażyna Sypniewska; Tomasz Tomasik; Adam Windak; Dorota Zozulińska-Ziółkiewicz; Barbara Cybulska
Journal:  Arch Med Sci       Date:  2021-11-08       Impact factor: 3.318

4.  A High-Cholesterol Diet Increases Toll-like Receptors and Other Harmful Factors in the Rabbit Myocardium: The Beneficial Effect of Statins.

Authors:  Alkistis Kapelouzou; Michalis Katsimpoulas; Christos Kontogiannis; Irene Lidoriki; Georgios Georgiopoulos; Christos Kourek; Christos Papageorgiou; Konstantinos S Mylonas; Spyridon Dritsas; Alexandros Charalabopoulos; Dennis V Cokkinos
Journal:  Curr Issues Mol Biol       Date:  2021-07-26       Impact factor: 2.976

5.  No benefits of statins for sudden cardiac death prevention in patients with heart failure and reduced ejection fraction: A meta-analysis of randomized controlled trials.

Authors:  Muaamar Al-Gobari; Hai-Ha Le; Mor Fall; François Gueyffier; Bernard Burnand
Journal:  PLoS One       Date:  2017-02-06       Impact factor: 3.240

6.  Diabetic retinopathy is associated with diastolic dysfunction in type 2 diabetic patients with non-ischemic dilated cardiomyopathy.

Authors:  Yoo-Ri Chung; Se-Jun Park; Ka Young Moon; Seoyoung Annie Choi; Hong-Seok Lim; Sung Wook Park; Jeong Hun Kim; Kihwang Lee
Journal:  Cardiovasc Diabetol       Date:  2017-07-06       Impact factor: 9.951

7.  Low apolipoprotein A-I levels in Friedreich's ataxia and in frataxin-deficient cells: Implications for therapy.

Authors:  QingQing Wang; Lili Guo; Cassandra J Strawser; Lauren A Hauser; Wei-Ting Hwang; Nathaniel W Snyder; David R Lynch; Clementina Mesaros; Ian A Blair
Journal:  PLoS One       Date:  2018-02-15       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.